Shots:

• QIAGEN has started the shipment of its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to the US for diagnosing the patients infected with COVID-19 under a new FDA’s policy- announced on Mar 16- 2020
• The QIAstat-Dx test is a multiplexed nucleic acid test that assesses samples such as nasopharyngeal swabs obtained from individuals suspected of the respiratory tract and can differentiate the SARS-CoV-2 from 20 other respiratory infections
• The kit requires < 1min. for preparing the sample and delivers results in ~1hr. The company is expected to submit EUA to the US FDA this week

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: QIAGEN